Abstract

Human islet amyloid polypeptide (hIAPP) is a naturally occurring, intrinsically disordered protein whose abnormal aggregation into amyloid fibrils is a pathological feature in type 2 diabetes, and its cross-aggregation with amyloid beta has been linked to an increased risk of Alzheimer’s disease. The soluble, oligomeric forms of hIAPP are the most toxic to β-cells in the pancreas. However, the structure of these oligomeric forms is difficult to characterise because of their intrinsic disorder and their tendency to rapidly aggregate into insoluble fibrils. Experimental studies of hIAPP have generally used non-physiological conditions to prevent aggregation, and they have been unable to describe its soluble monomeric and oligomeric structure at physiological conditions. Molecular dynamics (MD) simulations offer an alternative for the detailed characterisation of the monomeric structure of hIAPP and its aggregation in aqueous solution. This paper reviews the knowledge that has been gained by the use of MD simulations, and its relationship to experimental data for both hIAPP and rat IAPP. In particular, the influence of the choice of force field and water models, the choice of initial structure, and the configurational sampling method used, are discussed in detail. Characterisation of the solution structure of hIAPP and its mechanism of oligomerisation is important to understanding its cellular toxicity and its role in disease states, and may ultimately offer new opportunities for therapeutic interventions.

Highlights

  • The incidence of type 2 diabetes (T2D) is rapidly increasing, and in 2015 it was the sixth leading cause of disability [1]

  • It is believed that Human islet amyloid polypeptide (hIAPP) has interactions at the molecular level with Aβ that may result in an increased risk of developing Alzheimer’s disease (AD) in patients suffering from T2D [18,113]

  • Characterisation of the structure and aggregation of hIAPP is of the utmost importance due to its association with T2D, as well as its ability to cross-aggregate with other amyloidogenic proteins such as Aβ, which may in turn increase the likelihood of AD

Read more

Summary

Introduction

The incidence of type 2 diabetes (T2D) is rapidly increasing, and in 2015 it was the sixth leading cause of disability [1]. Characterisation of the solution structure of hIAPP in its monomeric form and its mechanism of oligomerisation is a key step in the understanding of its cellular toxicity and its role in disease. This could be instrumental for the prevention of the aggregation of hIAPP into toxic soluble oligomers and insoluble fibrils, and may offer a new therapeutic approach to treating or preventing T2D [17]. The interaction and possible cross-aggregation of these two proteins is poorly understood due to the limited structural knowledge of their soluble hetero-oligomeric forms

Experimental Studies of the Structure of hIAPP
Atomic
Structure of Fibrils
Structure the beta beta sheet sheet
Structure of the the Monomer
Structure
The Choice of Force Field
The Choice of Enhanced Sampling Method
MD Simulations Studies of the Initial Stages of Aggregation of hIAPP
11. Differences
Cross-Aggregation of hIAPP with Aβ
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call